On February 9, Nanjing TransThera Biosciences Co. Ltd., an enterprise in the Pilot Free Trade Zone Nanjing Area, announced the completion of C+ round of financing of over USD 50 million. In this round of financing, Co-Stone Capital was the lead-investor and Merchants Capital, the co-investor. The original shareholder, SDIC Venture Capital and Nanjing Summit Capital increased their investment, and China Renaissance acted as the exclusive financial advisor of this transaction.

As a highly capable platform company dedicated to the R&D of clinical-stage small molecule innovative drugs, TransThera has delivered four independently developed products that entered the stage of clinical development globally and a number of preclinical products in four years since its establishment, owing to the strong R&D and executive ability of its team.